Hot Chips - Glenmark Pharma
Ali On Content / 10 May 2010
The scrips in this column have been recommended with a short-term investment horizon and carry high risk. So, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations
Glenmark Pharma
BSE Code: 532296
Volume: 466794
CMP: 285.45
Glenmark’s latest out-licensing deal with Sanofi will restore some confidence in the company’s R&D effort. Besides some option value being built into the stock, it would also ease some of the pressure on Glenmark’s cash flows by funding its proprietary R&D spends. Glenmark will receive an upfront payment of USD 20 mn, milestone payments (which could reach a total of USD 325 mn) and royalties on sales. Sanofi will have exclusive marketing rights for North America, EU & Japan while Glenmark retains co-marketing rights in the US and 5 Eastern EU countries. Sanofi will retain co-marketing rights for 10 other countries, including Brazil, Russia and China. Glenmark retains exclusive rights in other markets. The cash flows from the deal would allow Glenmark to fund its proprietary R&D spend without depending too much on its generic cash flows. The stock may witness some northward move from the present levels and can be looked upon for both short- and medium-term gains.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.